Eli Lilly and Company (NYSE: LLY), a global healthcare and biopharmaceutical company, announced on Tuesday that it is constructing a new pharmaceutical manufacturing facility in North Carolina's Research Triangle Park.
The company said it will invest over USD470m in this state-of-the-art facility that will produce parenteral (or injectable) products and delivery devices. In addition, Lilly will create more than 400 jobs in highly skilled positions such as scientists, engineers, quality professionals and manufacturing operations.
"Life science companies like Lilly continue to choose North Carolina," said Roy Cooper, Governor of North Carolina. "Our exceptional workforce draws global companies as we continue to grow North Carolina into a worldwide hub for the biotechnology industry."
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial